Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

ABSTRACT Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis. Methods We inclu...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical and experimental allergy Ročník 55; číslo 3; s. 226 - 238
Hlavní autori: Sousa‐Pinto, Bernardo, Costa, Elísio M., Vieira, Rafael José, Pfaar, Oliver, Bedbrook, Anna, Amaral, Rita, Brussino, Luisa, Kvedariene, Violeta, Larenas‐Linnemann, Desiree E., Iinuma, Tomohisa, Pham‐Thi, Nhân, Regateiro, Frederico S., Taborda‐Barata, Luis, Ventura, Maria Teresa, Ansotegui, Ignacio J., Bergmann, Karl C., Canonica, G. Walter, Cardona, Victoria, Cecchi, Lorenzo, Cherrez‐Ojeda, Ivan, Cingi, Cemal, Cruz, Alvaro A., Del Giacco, Stefano, Devillier, Philippe, Fokkens, Wytske J., Gemicioglu, Bilun, Ivancevich, Juan Carlos, Kuna, Piotr, Louis, Renaud, Makris, Michael, Morais‐Almeida, Mario, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Pereira, Ana Margarida, Reitsma, Sietze, Robles‐Velasco, Karla, Rouadi, Philip W., Samolinski, Boleslaw, Sova, Milan, Toppila‐Salmi, Sanna K., Sastre, Joaquin, Valiulis, Arunas, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, Joao A., Bousquet, Jean, Anto, Josep M., Kupczyk, Maciej, Kulus, Marek, Roche, Nicolas, Scichilone, Nicola, Almeida, Rute, Bosnic‐Anticevich, Sinthia, Loureiro, Claudia Chaves, Vries, Govert, Giuliano, Antonio F. M., Jácome, Cristina, Kaidashev, Igor, Louis, Gilles, Lourenço, Olga, Makela, Mika, Mullol, Joaquim, O’Hehir, Robyn, Okamoto, Yoshitaka, Olze, Heidi, Romantowski, Jan, Rivero‐Yeverino, Daniela, Rodriguez‐Gonzalez, Monica, Savouré, Marine, Serpa, Faradiba S., Sheikh, Aziz, Sofiev, Mikhail, Sperl, Annette, Todo‐Bom, Ana, Tsiligianni, Ioanna, Valovirta, Erkka, Eerd, Michiel, Blain, Hubert, Boulet, Louis‐Philippe, Brusselle, Guy, Buhl, Roland, Charpin, Denis, Casale, Thomas, Chivato, Tomas, Correia‐de‐Sousa, Jaime, Corrigan, Christopher, Blay, Frédéric, Dykewicz, Mark, Fiocchi, Alessandro, Giovannini, Mattia, Jutel, Marek, Keil, Thomas, La Grutta, Stefania, Lipworth, Brian, Papi, Alberto, Cordeiro, Carlos Robalo, Torres, Maria J., Usmani, Omar S., Brightling, Christopher
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Wiley Subscription Services, Inc 01.03.2025
John Wiley and Sons Inc
Predmet:
ISSN:0954-7894, 1365-2222, 1365-2222
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract ABSTRACT Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis. Methods We included regular European MASK‐air users with self‐reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine‐fluticasone. We assessed weeks during which patients answered the MASK‐air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom‐medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. Results We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine‐fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self‐reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co‐medication. The sensitivity analyses displayed similar results. Conclusions A high adherence was found in patients reporting regular use of MASK‐air. Different adherence patterns were found for INCS compared to OAH or azelastine‐fluticasone that are likely to impact guidelines. In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
AbstractList Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis.BACKGROUNDAdherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis.We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data.METHODSWe included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data.We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results.RESULTSWe assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results.A high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines.CONCLUSIONSA high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines.
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
BackgroundAdherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis.MethodsWe included regular European MASK‐air users with self‐reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine‐fluticasone. We assessed weeks during which patients answered the MASK‐air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom‐medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data.ResultsWe assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine‐fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self‐reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co‐medication. The sensitivity analyses displayed similar results.ConclusionsA high adherence was found in patients reporting regular use of MASK‐air. Different adherence patterns were found for INCS compared to OAH or azelastine‐fluticasone that are likely to impact guidelines.
ABSTRACT Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis. Methods We included regular European MASK‐air users with self‐reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine‐fluticasone. We assessed weeks during which patients answered the MASK‐air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom‐medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. Results We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine‐fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self‐reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co‐medication. The sensitivity analyses displayed similar results. Conclusions A high adherence was found in patients reporting regular use of MASK‐air. Different adherence patterns were found for INCS compared to OAH or azelastine‐fluticasone that are likely to impact guidelines. In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis. We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results. A high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines.
Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis. Methods We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. Results We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results. Conclusions A high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines.
Author Rivero‐Yeverino, Daniela
Scichilone, Nicola
Klimek, Ludger
Robles‐Velasco, Karla
Canonica, G. Walter
Blay, Frédéric
Valovirta, Erkka
Bergmann, Karl C.
O’Hehir, Robyn
Gradauskiene, Brigita
Cingi, Cemal
Sova, Milan
Pereira, Ana Margarida
Okamoto, Yoshitaka
Boulet, Louis‐Philippe
Pfaar, Oliver
Bousquet, Jean
Kaidashev, Igor
Pépin, Jean‐Louis
Sheikh, Aziz
Jutel, Marek
Cordeiro, Carlos Robalo
Bosnic‐Anticevich, Sinthia
Taborda‐Barata, Luis
Ventura, Maria Teresa
Dykewicz, Mark
Bedbrook, Anna
Pham‐Thi, Nhân
Laune, Daniel
Kuna, Piotr
Brusselle, Guy
Maurer, Marcus
Almeida, Rute
Todo‐Bom, Ana
Nadif, Rachel
Rouadi, Philip W.
Regateiro, Frederico S.
Cardona, Victoria
Makela, Mika
Buhl, Roland
Mullol, Joaquim
Roche, Nicolas
La Grutta, Stefania
Blain, Hubert
Sperl, Annette
Shamji, Mohamed H.
Tsiligianni, Ioanna
Zuberbier, Torsten
Kraxner, Helga
Romantowski, Jan
Corrigan, Christopher
Giuliano, Antonio F. M.
Louis, Gilles
Toppila‐Salmi, Sanna K.
Cherrez‐Ojeda, Ivan
Samolinski, Boleslaw
Niedoszytko, Marek
Ansotegui, Ignacio J.
Anto, Josep M.
Jassem, Ewa
Torres,
AuthorAffiliation 65 Department of Respiratory Medicine and Tuberculosis University Hospital Brno Czech Republic
11 Department of Cardiovascular and Respiratory Sciences, Porto Health School Polytechnic Institute of Porto Porto Portugal
29 Institute of Allergology, Charité–Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
31 Department of Biomedical Sciences Humanitas University, Pieve Emanuele Milan Italy
58 Division of Allergy and Clinical Immunology, Department of Medicine 'Santa Maria della Speranza' Hospital, Battipaglia Salerno Italy
10 Department of Women's and Children's Health, Paediatric Research Uppsala University Uppsala Sweden
1 MEDCIDS–Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine University of Porto Porto Portugal
63 Department of Otorhinolaryngology, Head and Neck Surgery Dar Al Shifa Hospital Salmiya Kuwait
7 ARIA Montpellier France
62 Department of Otolaryngology, Head and N
AuthorAffiliation_xml – name: 14 Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine Vilnius University Vilnius Lithuania
– name: 49 KYomed INNOV Montpellier France
– name: 65 Department of Respiratory Medicine and Tuberculosis University Hospital Brno Czech Republic
– name: 12 Department of Medical Sciences University of Torino Torino Italy
– name: 22 Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine University of Coimbra Coimbra Portugal
– name: 71 Clinic of Asthma, Allergy, and Chronic Lung Diseases Vilnius Lithuania
– name: 31 Department of Biomedical Sciences Humanitas University, Pieve Emanuele Milan Italy
– name: 48 Department of Otorhinolaryngology, Head and Neck Surgery Semmelweis University Budapest Hungary
– name: 68 Allergy Service, Fundacion Jimenez Diaz Universidad Autonoma de Madrid, CIBERES‐ISCIII Madrid Spain
– name: 15 Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine Vilnius University Vilnius Lithuania
– name: 13 Allergy and Clinical Immunology Unit Mauriziano Hospital Torino Italy
– name: 56 Department of Allergology Medical University of Gdańsk Gdansk Poland
– name: 37 Respiralab Research Group Guayaquil Guayas Ecuador
– name: 53 Allergy Center CUF Descobertas Hospital Lisbon Portugal
– name: 51 GIGA I3 Research Group University of Liège Liège Belgium
– name: 47 Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital Medical University of Lodz Lodz Poland
– name: 7 ARIA Montpellier France
– name: 11 Department of Cardiovascular and Respiratory Sciences, Porto Health School Polytechnic Institute of Porto Porto Portugal
– name: 6 Medical Consulting Czarlewski Levallois France
– name: 21 Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra Unidade Local de Saúde de Coimbra Coimbra Portugal
– name: 59 Agency of Health ASL Salerno Italy
– name: 46 Servicio de Alergia e Immunologia Clinica Santa Isabel Buenos Aires Argentina
– name: 74 University Clinic of Respiratory and Allergic Diseases Golnik Slovenia
– name: 42 Department of Otorhinolaryngology Amsterdam University Medical Centres, AMC Amsterdam the Netherlands
– name: 45 Skin and Allergy Hospital Helsinki University Hospital, and University of Helsinki Helsinki Finland
– name: 66 Department of Otorhinolaryngology University of Eastern Finland and the North Savo Wellbeing Services County Kuopio Finland
– name: 24 UBIAir–Clinical & Experimental Lung Centre and CICS‐UBI Health Sciences Research Centre University of Beira Interior Covilhã Portugal
– name: 33 Allergy Section, Department of Internal Medicine Hospital Vall d'Hebron Barcelona Spain
– name: 32 Asthma and Allergy Unit IRCCS Humanitas Research Hospital, Rozzano Milan Italy
– name: 2 CINTESIS@RISE–Centre for Health Technology and Services Research, Health Research Network, Faculty of Medicine University of Porto Porto Portugal
– name: 52 Allergy Unit “D Kalogeromitros”, 2nd Dpt of Dermatology and Venereology, National & Kapodistrian University of Athens “Attikon” University Hospital Athens Greece
– name: 50 Department of Pulmonary Medicine CHU Liège Liège Belgium
– name: 40 Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital “Duilio Casula” University of Cagliari Cagliari Italy
– name: 61 PaCeIT–Patient Centered Innovation and Technologies, Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine University of Porto Porto Portugal
– name: 16 Center of Excellence in Asthma and Allergy Médica Sur Clinical Foundation and Hospital México City Mexico
– name: 39 Fundaçao ProAR Federal University of Bahia and GARD/WHO Planning Group Salvador Bahia Brazil
– name: 57 Allergy Department, 2nd Pediatric Clinic University of Athens Athens Greece
– name: 69 Interdisciplinary Research Group of Human Ecology, Institute of Clinical Medicine and Institute of Health Sciences Medical Faculty of Vilnius University Vilnius Lithuania
– name: 36 Universidad Espíritu Santo Samborondón Ecuador
– name: 29 Institute of Allergology, Charité–Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
– name: 4 Department of Otolaryngology, Head and Neck Surgery Universitätsmedizin Mainz Mainz Germany
– name: 67 Department of Allergy, Skin and Allergy Hospital, Inflammation Center Helsinki University Hospital and University of Helsinki Helsinki Finland
– name: 60 Postgraduate Program in Allergy and Clinical Immunology University of Naples Federico II Naples Italy
– name: 30 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology Berlin Germany
– name: 25 Department of Immunoallergology Cova da Beira University Hospital Centre Covilhã Portugal
– name: 73 Faculty of Medicine University of Ljubljana Ljubljana Slovenia
– name: 35 SOS Allergology and Clinical Immunology USL Toscana Centro Prato Italy
– name: 58 Division of Allergy and Clinical Immunology, Department of Medicine 'Santa Maria della Speranza' Hospital, Battipaglia Salerno Italy
– name: 43 Department of Pulmonary Diseases, Istanbul University‐Cerrahpaşa Cerrahpaşa Faculty of Medicine Istanbul Turkey
– name: 64 Department of Prevention of Environmental Hazards, Allergology and Immunology Medical University of Warsaw Warsaw Poland
– name: 17 Department of Otorhinolaryngology Chiba University Hospital Chiba Japan
– name: 70 Clinic of Children's Diseases, Institute of Clinical Medicine and Institute of Health Sciences Medical Faculty of Vilnius University Vilnius Lithuania
– name: 19 IRBA (Institut de Recherche Bio‐Médicale des Armées) Bretigny sur Orge France
– name: 38 Medical Faculty, ENT Department Eskisehir Osmangazi University Eskisehir Turkey
– name: 72 Department of Pulmonary Diseases Celal Bayar University, Faculty of Medicine Manisa Turkey
– name: 41 VIM Suresnes, UMR 0892, Pôle des Maladies des Voies Respiratoires, Hôpital Foch Université Paris‐Saclay Suresnes France
– name: 3 CINTESIS@RISE, Biochemistry Lab, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing University of Porto Porto Portugal
– name: 23 Institute of Immunology, Faculty of Medicine University of Coimbra Coimbra Portugal
– name: 8 Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg Philipps‐Universität Marburg Marburg Germany
– name: 55 ClinCompetence Cologne GmbH Cologne Germany
– name: 62 Department of Otolaryngology, Head and Neck Surgery Eye and Ear University Hospital Beirut Lebanon
– name: 28 Department of Allergy and Immunology Hospital Quironsalud Bizkaia Bilbao Spain
– name: 18 Ecole Polytechnique de Palaiseau Palaiseau France
– name: 1 MEDCIDS–Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine University of Porto Porto Portugal
– name: 34 ARADyAL Research Network Barcelona Spain
– name: 27 Institute of Sciences of Food Production National Research Council (ISPA‐CNR) Bari Italy
– name: 44 Institute of Pulmonology and Tuberculosis Istanbul University‐Cerrahpaşa Istanbul Turkey
– name: 26 University of Bari Medical School Bari Italy
– name: 54 Institute of Medical Statistics and Computational Biology University of Cologne Cologne Germany
– name: 9 MASK‐Air SAS Montpellier France
– name: 10 Department of Women's and Children's Health, Paediatric Research Uppsala University Uppsala Sweden
– name: 5 Center for Rhinology and Allergology Wiesbaden Germany
– name: 20 Université Paris Cité Paris France
– name: 63 Department of Otorhinolaryngology, Head and Neck Surgery Dar Al Shifa Hospital Salmiya Kuwait
Author_xml – sequence: 1
  givenname: Bernardo
  surname: Sousa‐Pinto
  fullname: Sousa‐Pinto, Bernardo
  organization: University of Porto
– sequence: 2
  givenname: Elísio M.
  surname: Costa
  fullname: Costa, Elísio M.
  organization: University of Porto
– sequence: 3
  givenname: Rafael José
  surname: Vieira
  fullname: Vieira, Rafael José
  organization: University of Porto
– sequence: 6
  givenname: Oliver
  orcidid: 0000-0003-4374-9639
  surname: Pfaar
  fullname: Pfaar, Oliver
  organization: Philipps‐Universität Marburg
– sequence: 7
  givenname: Anna
  surname: Bedbrook
  fullname: Bedbrook, Anna
  organization: MASK‐Air SAS
– sequence: 8
  givenname: Rita
  orcidid: 0000-0002-0233-830X
  surname: Amaral
  fullname: Amaral, Rita
  organization: Polytechnic Institute of Porto
– sequence: 9
  givenname: Luisa
  surname: Brussino
  fullname: Brussino, Luisa
  organization: Mauriziano Hospital
– sequence: 10
  givenname: Violeta
  surname: Kvedariene
  fullname: Kvedariene, Violeta
  organization: Vilnius University
– sequence: 11
  givenname: Desiree E.
  surname: Larenas‐Linnemann
  fullname: Larenas‐Linnemann, Desiree E.
  organization: Médica Sur Clinical Foundation and Hospital
– sequence: 12
  givenname: Tomohisa
  surname: Iinuma
  fullname: Iinuma, Tomohisa
  organization: Chiba University Hospital
– sequence: 13
  givenname: Nhân
  surname: Pham‐Thi
  fullname: Pham‐Thi, Nhân
  organization: Université Paris Cité
– sequence: 14
  givenname: Frederico S.
  surname: Regateiro
  fullname: Regateiro, Frederico S.
  organization: University of Beira Interior
– sequence: 15
  givenname: Luis
  surname: Taborda‐Barata
  fullname: Taborda‐Barata, Luis
  organization: Cova da Beira University Hospital Centre
– sequence: 16
  givenname: Maria Teresa
  surname: Ventura
  fullname: Ventura, Maria Teresa
  organization: National Research Council (ISPA‐CNR)
– sequence: 17
  givenname: Ignacio J.
  surname: Ansotegui
  fullname: Ansotegui, Ignacio J.
  organization: Hospital Quironsalud Bizkaia
– sequence: 18
  givenname: Karl C.
  surname: Bergmann
  fullname: Bergmann, Karl C.
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology
– sequence: 19
  givenname: G. Walter
  surname: Canonica
  fullname: Canonica, G. Walter
  organization: IRCCS Humanitas Research Hospital, Rozzano
– sequence: 20
  givenname: Victoria
  surname: Cardona
  fullname: Cardona, Victoria
  organization: ARADyAL Research Network
– sequence: 21
  givenname: Lorenzo
  surname: Cecchi
  fullname: Cecchi, Lorenzo
  organization: USL Toscana Centro
– sequence: 22
  givenname: Ivan
  orcidid: 0000-0002-1610-239X
  surname: Cherrez‐Ojeda
  fullname: Cherrez‐Ojeda, Ivan
  organization: Respiralab Research Group
– sequence: 23
  givenname: Cemal
  surname: Cingi
  fullname: Cingi, Cemal
  organization: Eskisehir Osmangazi University
– sequence: 24
  givenname: Alvaro A.
  surname: Cruz
  fullname: Cruz, Alvaro A.
  organization: Federal University of Bahia and GARD/WHO Planning Group
– sequence: 25
  givenname: Stefano
  surname: Del Giacco
  fullname: Del Giacco, Stefano
  organization: University of Cagliari
– sequence: 26
  givenname: Philippe
  surname: Devillier
  fullname: Devillier, Philippe
  organization: Université Paris‐Saclay
– sequence: 27
  givenname: Wytske J.
  surname: Fokkens
  fullname: Fokkens, Wytske J.
  organization: Amsterdam University Medical Centres, AMC
– sequence: 28
  givenname: Bilun
  orcidid: 0000-0001-5953-4881
  surname: Gemicioglu
  fullname: Gemicioglu, Bilun
  organization: Istanbul University‐Cerrahpaşa
– sequence: 30
  givenname: Juan Carlos
  surname: Ivancevich
  fullname: Ivancevich, Juan Carlos
  organization: Clinica Santa Isabel
– sequence: 31
  givenname: Piotr
  surname: Kuna
  fullname: Kuna, Piotr
  organization: Medical University of Lodz
– sequence: 34
  givenname: Renaud
  surname: Louis
  fullname: Louis, Renaud
  organization: University of Liège
– sequence: 35
  givenname: Michael
  surname: Makris
  fullname: Makris, Michael
  organization: “Attikon” University Hospital
– sequence: 36
  givenname: Mario
  surname: Morais‐Almeida
  fullname: Morais‐Almeida, Mario
  organization: CUF Descobertas Hospital
– sequence: 38
  givenname: Marek
  surname: Niedoszytko
  fullname: Niedoszytko, Marek
  organization: Medical University of Gdańsk
– sequence: 39
  givenname: Nikolaos G.
  surname: Papadopoulos
  fullname: Papadopoulos, Nikolaos G.
  organization: University of Athens
– sequence: 41
  givenname: Ana Margarida
  orcidid: 0000-0002-5468-0932
  surname: Pereira
  fullname: Pereira, Ana Margarida
  organization: University of Porto
– sequence: 42
  givenname: Sietze
  surname: Reitsma
  fullname: Reitsma, Sietze
  organization: Amsterdam University Medical Centres, AMC
– sequence: 43
  givenname: Karla
  surname: Robles‐Velasco
  fullname: Robles‐Velasco, Karla
  organization: Respiralab Research Group
– sequence: 44
  givenname: Philip W.
  surname: Rouadi
  fullname: Rouadi, Philip W.
  organization: Dar Al Shifa Hospital
– sequence: 45
  givenname: Boleslaw
  surname: Samolinski
  fullname: Samolinski, Boleslaw
  organization: Medical University of Warsaw
– sequence: 46
  givenname: Milan
  surname: Sova
  fullname: Sova, Milan
  organization: University Hospital
– sequence: 47
  givenname: Sanna K.
  surname: Toppila‐Salmi
  fullname: Toppila‐Salmi, Sanna K.
  organization: Helsinki University Hospital and University of Helsinki
– sequence: 48
  givenname: Joaquin
  orcidid: 0000-0003-4689-6837
  surname: Sastre
  fullname: Sastre, Joaquin
  organization: Universidad Autonoma de Madrid, CIBERES‐ISCIII
– sequence: 49
  givenname: Arunas
  surname: Valiulis
  fullname: Valiulis, Arunas
  organization: Clinic of Asthma, Allergy, and Chronic Lung Diseases
– sequence: 50
  givenname: Arzu
  surname: Yorgancioglu
  fullname: Yorgancioglu, Arzu
  organization: Celal Bayar University, Faculty of Medicine
– sequence: 51
  givenname: Mihaela
  orcidid: 0000-0003-0515-5207
  surname: Zidarn
  fullname: Zidarn, Mihaela
  organization: University Clinic of Respiratory and Allergic Diseases
– sequence: 52
  givenname: Torsten
  surname: Zuberbier
  fullname: Zuberbier, Torsten
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology
– sequence: 53
  givenname: Joao A.
  surname: Fonseca
  fullname: Fonseca, Joao A.
  organization: University of Porto
– sequence: 54
  givenname: Jean
  orcidid: 0000-0002-4061-4766
  surname: Bousquet
  fullname: Bousquet, Jean
  email: jean.bousquet@orange.fr
  organization: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology
– sequence: 56
  givenname: Josep M.
  surname: Anto
  fullname: Anto, Josep M.
– sequence: 57
  givenname: Maciej
  surname: Kupczyk
  fullname: Kupczyk, Maciej
– sequence: 58
  givenname: Marek
  surname: Kulus
  fullname: Kulus, Marek
– sequence: 59
  givenname: Nicolas
  surname: Roche
  fullname: Roche, Nicolas
– sequence: 60
  givenname: Nicola
  surname: Scichilone
  fullname: Scichilone, Nicola
– sequence: 61
  givenname: Rute
  surname: Almeida
  fullname: Almeida, Rute
– sequence: 62
  givenname: Sinthia
  surname: Bosnic‐Anticevich
  fullname: Bosnic‐Anticevich, Sinthia
– sequence: 64
  givenname: Claudia Chaves
  surname: Loureiro
  fullname: Loureiro, Claudia Chaves
– sequence: 65
  givenname: Govert
  surname: Vries
  fullname: Vries, Govert
– sequence: 66
  givenname: Antonio F. M.
  surname: Giuliano
  fullname: Giuliano, Antonio F. M.
– sequence: 67
  givenname: Cristina
  surname: Jácome
  fullname: Jácome, Cristina
– sequence: 68
  givenname: Igor
  surname: Kaidashev
  fullname: Kaidashev, Igor
– sequence: 69
  givenname: Gilles
  surname: Louis
  fullname: Louis, Gilles
– sequence: 70
  givenname: Olga
  surname: Lourenço
  fullname: Lourenço, Olga
– sequence: 71
  givenname: Mika
  surname: Makela
  fullname: Makela, Mika
– sequence: 73
  givenname: Joaquim
  surname: Mullol
  fullname: Mullol, Joaquim
– sequence: 75
  givenname: Robyn
  surname: O’Hehir
  fullname: O’Hehir, Robyn
– sequence: 76
  givenname: Yoshitaka
  surname: Okamoto
  fullname: Okamoto, Yoshitaka
– sequence: 78
  givenname: Heidi
  surname: Olze
  fullname: Olze, Heidi
– sequence: 81
  givenname: Jan
  surname: Romantowski
  fullname: Romantowski, Jan
– sequence: 82
  givenname: Daniela
  surname: Rivero‐Yeverino
  fullname: Rivero‐Yeverino, Daniela
– sequence: 83
  givenname: Monica
  surname: Rodriguez‐Gonzalez
  fullname: Rodriguez‐Gonzalez, Monica
– sequence: 85
  givenname: Marine
  surname: Savouré
  fullname: Savouré, Marine
– sequence: 86
  givenname: Faradiba S.
  surname: Serpa
  fullname: Serpa, Faradiba S.
– sequence: 88
  givenname: Aziz
  surname: Sheikh
  fullname: Sheikh, Aziz
– sequence: 90
  givenname: Mikhail
  surname: Sofiev
  fullname: Sofiev, Mikhail
– sequence: 91
  givenname: Annette
  surname: Sperl
  fullname: Sperl, Annette
– sequence: 92
  givenname: Ana
  surname: Todo‐Bom
  fullname: Todo‐Bom, Ana
– sequence: 93
  givenname: Ioanna
  surname: Tsiligianni
  fullname: Tsiligianni, Ioanna
– sequence: 94
  givenname: Erkka
  surname: Valovirta
  fullname: Valovirta, Erkka
– sequence: 95
  givenname: Michiel
  surname: Eerd
  fullname: Eerd, Michiel
– sequence: 96
  givenname: Hubert
  surname: Blain
  fullname: Blain, Hubert
– sequence: 97
  givenname: Louis‐Philippe
  surname: Boulet
  fullname: Boulet, Louis‐Philippe
– sequence: 98
  givenname: Guy
  surname: Brusselle
  fullname: Brusselle, Guy
– sequence: 99
  givenname: Roland
  surname: Buhl
  fullname: Buhl, Roland
– sequence: 100
  givenname: Denis
  surname: Charpin
  fullname: Charpin, Denis
– sequence: 101
  givenname: Thomas
  surname: Casale
  fullname: Casale, Thomas
– sequence: 102
  givenname: Tomas
  surname: Chivato
  fullname: Chivato, Tomas
– sequence: 103
  givenname: Jaime
  surname: Correia‐de‐Sousa
  fullname: Correia‐de‐Sousa, Jaime
– sequence: 104
  givenname: Christopher
  surname: Corrigan
  fullname: Corrigan, Christopher
– sequence: 105
  givenname: Frédéric
  surname: Blay
  fullname: Blay, Frédéric
– sequence: 106
  givenname: Mark
  surname: Dykewicz
  fullname: Dykewicz, Mark
– sequence: 107
  givenname: Alessandro
  surname: Fiocchi
  fullname: Fiocchi, Alessandro
– sequence: 108
  givenname: Mattia
  surname: Giovannini
  fullname: Giovannini, Mattia
– sequence: 110
  givenname: Marek
  surname: Jutel
  fullname: Jutel, Marek
– sequence: 111
  givenname: Thomas
  surname: Keil
  fullname: Keil, Thomas
– sequence: 112
  givenname: Stefania
  surname: La Grutta
  fullname: La Grutta, Stefania
– sequence: 113
  givenname: Brian
  surname: Lipworth
  fullname: Lipworth, Brian
– sequence: 114
  givenname: Alberto
  surname: Papi
  fullname: Papi, Alberto
– sequence: 117
  givenname: Carlos Robalo
  surname: Cordeiro
  fullname: Cordeiro, Carlos Robalo
– sequence: 118
  givenname: Maria J.
  surname: Torres
  fullname: Torres, Maria J.
– sequence: 119
  givenname: Omar S.
  surname: Usmani
  fullname: Usmani, Omar S.
– sequence: 122
  givenname: Christopher
  surname: Brightling
  fullname: Brightling, Christopher
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39956639$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-557931$$DView record from Swedish Publication Index (Uppsala universitet)
BookMark eNp1ks9uEzEQxi1URNPAgRdAlriA1G3t9a697gWt0vBHFIFI4Wo53tnE1cYO9m6r3HgEnpEnwSEpohXMxYf5fZ9mPN8ROnDeAUJPKTmhqU4N6BNBCCkeoBFlvMzyVAdoRGRZZKKSxSE6ivEqEayU1SN0yKQsOWdyhOZ1s4QAzgDuPb4MoPsVuB5bh-uug7CwBn9eWmd7G_H5EKxb4H4J-JNPXYdnoKN3W3o6BL-GM1zjD_Xs_c_vP7QNeNYPzeYxetjqLsKT_TtGX15PLydvs4uPb95N6ovMlJQUmaSa5wIYnefA54UoIdekBZ4bQkrG26LNDddcGM5FQQSp8kZDw3RDZStZ1bAxOt75xhtYD3O1Dnalw0Z5bdW5_VorHxZqGFRZCslowl_t8MSuoDFp66C7O6q7HWeXauGvFaWSVBWrksOLvUPw3waIvVrZaKDrtAM_RMUoF4JKmsuEPr-HXvkhuPQdiRIip2x7nDF69vdIf2a5PVcCTneACT7GAK0ytte99dsJbacoUdtAqBQI9TsQSfHynuLW9F_s3v3GdrD5P6gm03qn-AV-McPu
CitedBy_id crossref_primary_10_1111_cea_70023
crossref_primary_10_3390_medicina61091639
Cites_doi 10.1016/j.jaip.2024.06.040
10.1111/all.15199
10.1016/j.jaip.2022.07.020
10.1007/s11882-014-0507-8
10.1002/clt2.12062
10.1007/s12016‐016‐8542‐y
10.1016/j.jaci.2020.07.007
10.1097/ACI.0000000000000331
10.1136/bmj.g7731
10.1016/j.jaci.2017.03.050
10.1186/s13601-020-00342-x
10.1111/all.13406
10.1111/all.15371
10.1186/s13601-019-0252-0
10.3389/fphar.2018.01290
10.1016/j.jaci.2019.01.053
10.1111/cea.13333
10.1111/j.1365-2222.2012.04052.x
10.1002/clt2.12215
10.1111/all.15275
10.1016/j.jaci.2024.04.016
ContentType Journal Article
Contributor Scichilone, Nicola
Pépin, Jean-Louis
Valovirta, Erkka
Gradauskiene, Brigita
Lourenço, Olga
Rodriguez-Gonzalez, Monica
Loureiro, Claudia Chaves
de Vries, Govert
Quirce, Santiago
Okamoto, Yoshitaka
Kaidashev, Igor
Sheikh, Aziz
Jutel, Marek
Cordeiro, Carlos Robalo
Brightling, Christopher
Kulus, Marek
Braido, Fulvio
Fiocchi, Alessandro
Dykewicz, Mark
Ollert, Markus
Todo-Bom, Ana
Keil, Thomas
Shamji, Mohamed H
Savouré, Marine
Brusselle, Guy
Maurer, Marcus
Almeida, Rute
Sofiev, Mikhail
Anto, Josep M
Casale, Thomas
Nadif, Rachel
Jácome, Cristina
O'Hehir, Robyn
Olze, Heidi
Rivero-Yeverino, Daniela
Chivato, Tomas
Usmani, Omar S
Boulet, Louis-Philippe
Giovannini, Mattia
Makela, Mika
Papi, Alberto
Buhl, Roland
Mullol, Joaquim
Puggioni, Francesca
Roche, Nicolas
van Eerd, Michiel
La Grutta, Stefania
Bonini, Matteo
Charpin, Denis
Correia-de-Sousa, Jaime
Blain, Hubert
Sperl, Annette
Torres, Maria J
Tsiligianni, Ioanna
de Blay, Frédéric
Serpa, Faradiba S
Giuliano, Antonio F M
Ulrik, Charlotte Suppli
Pétré, Benoit
Romantowski, Jan
Corrigan, Christopher
Louis, Gi
Contributor_xml – sequence: 1
  givenname: Josep M
  surname: Anto
  fullname: Anto, Josep M
– sequence: 2
  givenname: Maciej
  surname: Kupczyk
  fullname: Kupczyk, Maciej
– sequence: 3
  givenname: Marek
  surname: Kulus
  fullname: Kulus, Marek
– sequence: 4
  givenname: Nicolas
  surname: Roche
  fullname: Roche, Nicolas
– sequence: 5
  givenname: Nicola
  surname: Scichilone
  fullname: Scichilone, Nicola
– sequence: 6
  givenname: Rute
  surname: Almeida
  fullname: Almeida, Rute
– sequence: 7
  givenname: Sinthia
  surname: Bosnic-Anticevich
  fullname: Bosnic-Anticevich, Sinthia
– sequence: 8
  givenname: Fulvio
  surname: Braido
  fullname: Braido, Fulvio
– sequence: 9
  givenname: Claudia Chaves
  surname: Loureiro
  fullname: Loureiro, Claudia Chaves
– sequence: 10
  givenname: Govert
  surname: de Vries
  fullname: de Vries, Govert
– sequence: 11
  givenname: Antonio F M
  surname: Giuliano
  fullname: Giuliano, Antonio F M
– sequence: 12
  givenname: Cristina
  surname: Jácome
  fullname: Jácome, Cristina
– sequence: 13
  givenname: Igor
  surname: Kaidashev
  fullname: Kaidashev, Igor
– sequence: 14
  givenname: Gilles
  surname: Louis
  fullname: Louis, Gilles
– sequence: 15
  givenname: Olga
  surname: Lourenço
  fullname: Lourenço, Olga
– sequence: 16
  givenname: Mika
  surname: Makela
  fullname: Makela, Mika
– sequence: 17
  givenname: Marcus
  surname: Maurer
  fullname: Maurer, Marcus
– sequence: 18
  givenname: Joaquim
  surname: Mullol
  fullname: Mullol, Joaquim
– sequence: 19
  givenname: Rachel
  surname: Nadif
  fullname: Nadif, Rachel
– sequence: 20
  givenname: Robyn
  surname: O'Hehir
  fullname: O'Hehir, Robyn
– sequence: 21
  givenname: Yoshitaka
  surname: Okamoto
  fullname: Okamoto, Yoshitaka
– sequence: 22
  givenname: Markus
  surname: Ollert
  fullname: Ollert, Markus
– sequence: 23
  givenname: Heidi
  surname: Olze
  fullname: Olze, Heidi
– sequence: 24
  givenname: Benoit
  surname: Pétré
  fullname: Pétré, Benoit
– sequence: 25
  givenname: Francesca
  surname: Puggioni
  fullname: Puggioni, Francesca
– sequence: 26
  givenname: Jan
  surname: Romantowski
  fullname: Romantowski, Jan
– sequence: 27
  givenname: Daniela
  surname: Rivero-Yeverino
  fullname: Rivero-Yeverino, Daniela
– sequence: 28
  givenname: Monica
  surname: Rodriguez-Gonzalez
  fullname: Rodriguez-Gonzalez, Monica
– sequence: 29
  givenname: Ana
  surname: Sá-Sousa
  fullname: Sá-Sousa, Ana
– sequence: 30
  givenname: Marine
  surname: Savouré
  fullname: Savouré, Marine
– sequence: 31
  givenname: Faradiba S
  surname: Serpa
  fullname: Serpa, Faradiba S
– sequence: 32
  givenname: Mohamed H
  surname: Shamji
  fullname: Shamji, Mohamed H
– sequence: 33
  givenname: Aziz
  surname: Sheikh
  fullname: Sheikh, Aziz
– sequence: 34
  givenname: Charlotte Suppli
  surname: Ulrik
  fullname: Ulrik, Charlotte Suppli
– sequence: 35
  givenname: Mikhail
  surname: Sofiev
  fullname: Sofiev, Mikhail
– sequence: 36
  givenname: Annette
  surname: Sperl
  fullname: Sperl, Annette
– sequence: 37
  givenname: Ana
  surname: Todo-Bom
  fullname: Todo-Bom, Ana
– sequence: 38
  givenname: Ioanna
  surname: Tsiligianni
  fullname: Tsiligianni, Ioanna
– sequence: 39
  givenname: Erkka
  surname: Valovirta
  fullname: Valovirta, Erkka
– sequence: 40
  givenname: Michiel
  surname: van Eerd
  fullname: van Eerd, Michiel
– sequence: 41
  givenname: Hubert
  surname: Blain
  fullname: Blain, Hubert
– sequence: 42
  givenname: Louis-Philippe
  surname: Boulet
  fullname: Boulet, Louis-Philippe
– sequence: 43
  givenname: Guy
  surname: Brusselle
  fullname: Brusselle, Guy
– sequence: 44
  givenname: Roland
  surname: Buhl
  fullname: Buhl, Roland
– sequence: 45
  givenname: Denis
  surname: Charpin
  fullname: Charpin, Denis
– sequence: 46
  givenname: Thomas
  surname: Casale
  fullname: Casale, Thomas
– sequence: 47
  givenname: Tomas
  surname: Chivato
  fullname: Chivato, Tomas
– sequence: 48
  givenname: Jaime
  surname: Correia-de-Sousa
  fullname: Correia-de-Sousa, Jaime
– sequence: 49
  givenname: Christopher
  surname: Corrigan
  fullname: Corrigan, Christopher
– sequence: 50
  givenname: Frédéric
  surname: de Blay
  fullname: de Blay, Frédéric
– sequence: 51
  givenname: Mark
  surname: Dykewicz
  fullname: Dykewicz, Mark
– sequence: 52
  givenname: Alessandro
  surname: Fiocchi
  fullname: Fiocchi, Alessandro
– sequence: 53
  givenname: Mattia
  surname: Giovannini
  fullname: Giovannini, Mattia
– sequence: 54
  givenname: Ewa
  surname: Jassem
  fullname: Jassem, Ewa
– sequence: 55
  givenname: Marek
  surname: Jutel
  fullname: Jutel, Marek
– sequence: 56
  givenname: Thomas
  surname: Keil
  fullname: Keil, Thomas
– sequence: 57
  givenname: Stefania
  surname: La Grutta
  fullname: La Grutta, Stefania
– sequence: 58
  givenname: Brian
  surname: Lipworth
  fullname: Lipworth, Brian
– sequence: 59
  givenname: Alberto
  surname: Papi
  fullname: Papi, Alberto
– sequence: 60
  givenname: Jean-Louis
  surname: Pépin
  fullname: Pépin, Jean-Louis
– sequence: 61
  givenname: Santiago
  surname: Quirce
  fullname: Quirce, Santiago
– sequence: 62
  givenname: Carlos Robalo
  surname: Cordeiro
  fullname: Cordeiro, Carlos Robalo
– sequence: 63
  givenname: Maria J
  surname: Torres
  fullname: Torres, Maria J
– sequence: 64
  givenname: Omar S
  surname: Usmani
  fullname: Usmani, Omar S
– sequence: 65
  givenname: Matteo
  surname: Bonini
  fullname: Bonini, Matteo
– sequence: 66
  givenname: Brigita
  surname: Gradauskiene
  fullname: Gradauskiene, Brigita
– sequence: 67
  givenname: Christopher
  surname: Brightling
  fullname: Brightling, Christopher
Copyright 2025 The Author(s). published by John Wiley & Sons Ltd.
2025 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
2025. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2025 The Author(s). published by John Wiley & Sons Ltd.
– notice: 2025 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
– notice: 2025. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
CorporateAuthor the MASK‐air think tank
MASK‐air think tank
CorporateAuthor_xml – name: the MASK‐air think tank
– name: MASK‐air think tank
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
5PM
ACNBI
ADTPV
AOWAS
D8T
DF2
ZZAVC
DOI 10.1111/cea.70004
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
SWEPUB Uppsala universitet full text
SwePub
SwePub Articles
SWEPUB Freely available online
SWEPUB Uppsala universitet
SwePub Articles full text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts

MEDLINE

Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2222
EndPage 238
ExternalDocumentID oai_DiVA_org_uu_557931
PMC11908838
39956639
10_1111_cea_70004
CEA70004
Genre researchArticle
Journal Article
GeographicLocations Europe
GeographicLocations_xml – name: Europe
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OB
1OC
24P
29B
31~
33P
36B
3O-
3SF
4.4
4P2
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
A8Z
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
EDH
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
BANNL
CITATION
O8X
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
5PM
ACNBI
ADTPV
AOWAS
D8T
DF2
ESTFP
ZZAVC
ID FETCH-LOGICAL-c5104-91a627e31b2e6b475e2a0fe62c00536f4f2c6a67c667407082daed3ad19f938d3
IEDL.DBID 24P
ISICitedReferencesCount 3
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001489641800011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0954-7894
1365-2222
IngestDate Tue Nov 04 16:37:33 EST 2025
Tue Nov 04 02:03:12 EST 2025
Fri Sep 05 12:00:25 EDT 2025
Mon Oct 06 17:41:22 EDT 2025
Mon Jul 21 06:07:15 EDT 2025
Sat Nov 29 08:04:33 EST 2025
Tue Nov 18 22:28:53 EST 2025
Sat Mar 15 09:20:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords mobile health
treatment adherence
allergic rhinitis
Language English
License Attribution
2025 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5104-91a627e31b2e6b475e2a0fe62c00536f4f2c6a67c667407082daed3ad19f938d3
Notes None for this specific study. MASK‐air has been supported by EU grants (from the Impact of air Pollution on Asthma and Rhinitis project of the European Institute of Innovation and Technology Health; Structural and Development Funds, Région Languedoc Roussillon, and Provence‐Alpes‐Côte d'Azur; Twinning, European Innovation Partnership on Active and Healthy Ageing, DG Santé and DG Connect; H2020 and Horizon Europe), Universidad Espíritu Santo, Samborondón, Ecuador, University of Liège and educational grants from Mylan‐Viatris, Allergologisk Laboratorium København, GlaxoSmithKline, Novartis, Stallergènes‐Greer, and Noucor.
Funding
A list of the think tank members appears in the ‘The MASK‐air think tank’ section.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Funding: None for this specific study. MASK‐air has been supported by EU grants (from the Impact of air Pollution on Asthma and Rhinitis project of the European Institute of Innovation and Technology Health; Structural and Development Funds, Région Languedoc Roussillon, and Provence‐Alpes‐Côte d'Azur; Twinning, European Innovation Partnership on Active and Healthy Ageing, DG Santé and DG Connect; H2020 and Horizon Europe), Universidad Espíritu Santo, Samborondón, Ecuador, University of Liège and educational grants from Mylan‐Viatris, Allergologisk Laboratorium København, GlaxoSmithKline, Novartis, Stallergènes‐Greer, and Noucor.
ORCID 0000-0003-4374-9639
0000-0002-5468-0932
0000-0002-0233-830X
0000-0001-5953-4881
0000-0003-0515-5207
0000-0002-4061-4766
0000-0003-4689-6837
0000-0002-1610-239X
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcea.70004
PMID 39956639
PQID 3177213000
PQPubID 36521
PageCount 13
ParticipantIDs swepub_primary_oai_DiVA_org_uu_557931
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11908838
proquest_miscellaneous_3167719129
proquest_journals_3177213000
pubmed_primary_39956639
crossref_citationtrail_10_1111_cea_70004
crossref_primary_10_1111_cea_70004
wiley_primary_10_1111_cea_70004_CEA70004
PublicationCentury 2000
PublicationDate March 2025
PublicationDateYYYYMMDD 2025-03-01
PublicationDate_xml – month: 03
  year: 2025
  text: March 2025
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
– name: Hoboken
PublicationTitle Clinical and experimental allergy
PublicationTitleAlternate Clin Exp Allergy
PublicationYear 2025
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 2014; 349
2017; 6
2018; 9
2015; 15
2019; 9
2023; 13
2021; 11
2023
2013; 43
2017; 17
2019; 49
2024; 154
2017; 140
1961
2018; 73
2020; 146
2022; 10
2024; 12
2022; 77
2020; 10
2019; 144
2016; 56
1988
e_1_2_12_4_1
e_1_2_12_3_1
e_1_2_12_6_1
e_1_2_12_5_1
e_1_2_12_19_1
e_1_2_12_18_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_16_1
e_1_2_12_21_1
e_1_2_12_22_1
e_1_2_12_23_1
e_1_2_12_24_1
e_1_2_12_25_1
e_1_2_12_26_1
(e_1_2_12_11_1) 2023
Cohen J. (e_1_2_12_15_1) 1988
Roethlisberger F. (e_1_2_12_20_1) 1961
e_1_2_12_14_1
e_1_2_12_13_1
e_1_2_12_12_1
e_1_2_12_8_1
Bosnic‐Anticevich S. (e_1_2_12_7_1) 2017; 6
e_1_2_12_10_1
e_1_2_12_9_1
40129182 - Clin Exp Allergy. 2025 Mar 24. doi: 10.1111/cea.70041.
References_xml – volume: 10
  start-page: 2878
  issue: 11
  year: 2022
  end-page: 2888
  article-title: The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value‐Added Medicines: As‐Needed Treatment in Allergic Rhinitis
  publication-title: Journal of Allergy and Clinical Immunology. In Practice
– volume: 17
  start-page: 23
  issue: 1
  year: 2017
  end-page: 27
  article-title: Rhinitis: Adherence to Treatment and New Technologies
  publication-title: Current Opinion in Allergy and Clinical Immunology
– volume: 146
  start-page: 721
  issue: 4
  year: 2020
  end-page: 767
  article-title: Rhinitis 2020: A Practice Parameter Update
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 144
  start-page: 135
  issue: 1
  year: 2019
  end-page: 143
  article-title: Mobile Technology Offers Novel Insights Into the Control and Treatment of Allergic Rhinitis: The MASK Study
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 56
  start-page: 161
  issue: 2
  year: 2016
  end-page: 173
  article-title: Allergy and Asthma Care in the Mobile Phone era
  publication-title: Clinical Reviews in Allergy & Immunology
– volume: 49
  start-page: 442
  issue: 4
  year: 2019
  end-page: 460
  article-title: Adherence to Treatment in Allergic Rhinitis Using Mobile Technology. The MASK Study
  publication-title: Clinical and Experimental Allergy
– volume: 12
  start-page: 2648
  year: 2024
  end-page: 2668.e2
  article-title: Concepts for the Development of Person‐Centred, Digitally‐Enabled, Artificial Intelligence‐Assisted ARIA Care Pathways (ARIA 2024)
  publication-title: Journal of Allergy and Clinical Immunology. In Practice
– volume: 140
  start-page: 950
  issue: 4
  year: 2017
  end-page: 958
  article-title: Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines‐2016 Revision
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 73
  start-page: 1763
  issue: 9
  year: 2018
  end-page: 1774
  article-title: Treatment of Allergic Rhinitis Using Mobile Technology With Real‐World Data: The MASK Observational Pilot Study
  publication-title: Allergy
– volume: 77
  start-page: 2147
  issue: 7
  year: 2022
  end-page: 2162
  article-title: Development and Validation of Combined Symptom‐Medication Scores for Allergic Rhinitis
  publication-title: Allergy
– volume: 154
  start-page: 340
  year: 2024
  end-page: 354
  article-title: Intranasal Antihistamines and Corticosteroids in Allergic Rhinitis: A Systematic Review and Meta‐Analysis
  publication-title: Journal of Allergy and Clinical Immunology
– year: 1961
– volume: 10
  start-page: 62
  issue: 1
  year: 2020
  article-title: Treatment of Allergic Rhinitis During and Outside the Pollen Season Using Mobile Technology. A MASK Study
  publication-title: Clinical and Translational Allergy
– volume: 6
  start-page: 1
  year: 2017
  end-page: 11
  article-title: Lack of Asthma and Rhinitis Control in General Practitioner‐Managed Patients Prescribed Fixed‐Dose Combination Therapy in Australia
  publication-title: Journal of Asthma
– volume: 77
  start-page: 3002
  issue: 10
  year: 2022
  end-page: 3014
  article-title: Comparison of Rhinitis Treatments Using MASK‐Air(R) Data and Considering the Minimal Important Difference
  publication-title: Allergy
– volume: 13
  issue: 1
  year: 2023
  article-title: Digitally‐Enabled, Patient‐Centred Care in Rhinitis and Asthma Multimorbidity: The ARIA‐MASK‐Air((R)) Approach
  publication-title: Clinical and Translational Allergy
– year: 2023
– volume: 9
  year: 2019
  article-title: Guidance to 2018 Good Practice: ARIA Digitally‐Enabled, Integrated, Person‐Centred Care for Rhinitis and Asthma
  publication-title: Clinical and Translational Allergy
– volume: 77
  start-page: 2699
  issue: 9
  year: 2022
  end-page: 2711
  article-title: Behavioural Patterns in Allergic Rhinitis Medication in Europe: A Study Using MASK‐Air((R)) Real‐World Data
  publication-title: Allergy
– volume: 11
  issue: 7
  year: 2021
  article-title: Validity, Reliability, and Responsiveness of Daily Monitoring Visual Analog Scales in MASK‐Air(R)
  publication-title: Clinical and Translational Allergy
– volume: 43
  start-page: 22
  issue: 1
  year: 2013
  end-page: 28
  article-title: Adherence to Pharmacological Treatment and Specific Immunotherapy in Allergic Rhinitis
  publication-title: Clinical and Experimental Allergy
– volume: 349
  year: 2014
  article-title: Bias in Observational Study Designs: Prospective Cohort Studies
  publication-title: BMJ
– volume: 15
  start-page: 10
  issue: 3
  year: 2015
  article-title: Motivating Patient Adherence to Allergic Rhinitis Treatments
  publication-title: Current Allergy and Asthma Reports
– volume: 9
  year: 2018
  article-title: A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes
  publication-title: Frontiers in Pharmacology
– start-page: 567
  year: 1988
– ident: e_1_2_12_25_1
  doi: 10.1016/j.jaip.2024.06.040
– ident: e_1_2_12_13_1
  doi: 10.1111/all.15199
– volume: 6
  start-page: 1
  year: 2017
  ident: e_1_2_12_7_1
  article-title: Lack of Asthma and Rhinitis Control in General Practitioner‐Managed Patients Prescribed Fixed‐Dose Combination Therapy in Australia
  publication-title: Journal of Asthma
– start-page: 567
  volume-title: Statistical Power Analysis for the Behavioral Sciences
  year: 1988
  ident: e_1_2_12_15_1
– ident: e_1_2_12_8_1
  doi: 10.1016/j.jaip.2022.07.020
– ident: e_1_2_12_19_1
  doi: 10.1007/s11882-014-0507-8
– ident: e_1_2_12_17_1
  doi: 10.1002/clt2.12062
– ident: e_1_2_12_18_1
  doi: 10.1007/s12016‐016‐8542‐y
– ident: e_1_2_12_3_1
  doi: 10.1016/j.jaci.2020.07.007
– ident: e_1_2_12_4_1
  doi: 10.1097/ACI.0000000000000331
– ident: e_1_2_12_16_1
  doi: 10.1136/bmj.g7731
– ident: e_1_2_12_2_1
  doi: 10.1016/j.jaci.2017.03.050
– ident: e_1_2_12_23_1
  doi: 10.1186/s13601-020-00342-x
– ident: e_1_2_12_21_1
  doi: 10.1111/all.13406
– ident: e_1_2_12_26_1
  doi: 10.1111/all.15371
– ident: e_1_2_12_10_1
  doi: 10.1186/s13601-019-0252-0
– ident: e_1_2_12_14_1
  doi: 10.3389/fphar.2018.01290
– ident: e_1_2_12_22_1
  doi: 10.1016/j.jaci.2019.01.053
– ident: e_1_2_12_12_1
  doi: 10.1111/cea.13333
– volume-title: Management of the Worker: An Account of a Research Program Conducted by the Western Electric Company, Hawthorne Works, Chicago
  year: 1961
  ident: e_1_2_12_20_1
– volume-title: Integrating Care to Prevent and Manage Chronic Diseases: Best Practices in Public Health
  year: 2023
  ident: e_1_2_12_11_1
– ident: e_1_2_12_5_1
  doi: 10.1111/j.1365-2222.2012.04052.x
– ident: e_1_2_12_9_1
  doi: 10.1002/clt2.12215
– ident: e_1_2_12_6_1
  doi: 10.1111/all.15275
– ident: e_1_2_12_24_1
  doi: 10.1016/j.jaci.2024.04.016
– reference: 40129182 - Clin Exp Allergy. 2025 Mar 24. doi: 10.1111/cea.70041.
SSID ssj0003598
Score 2.4736304
Snippet ABSTRACT Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to...
Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines...
BackgroundAdherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral...
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii)...
Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral...
SourceID swepub
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 226
SubjectTerms Adolescent
Adrenal Cortex Hormones - administration & dosage
Adrenal Cortex Hormones - therapeutic use
Adult
Allergic rhinitis
Anti-Allergic Agents - therapeutic use
Antihistamines
Asthma
Corticosteroids
Europe - epidemiology
Female
Fluticasone
Hay fever
Histamine Antagonists - administration & dosage
Histamine Antagonists - therapeutic use
Humans
Male
Medication Adherence
Middle Aged
Missing data
mobile health
Original
Phthalazines - therapeutic use
Pollen
Pollen - adverse effects
Pollen - immunology
Rhinitis
Rhinitis, Allergic - drug therapy
Rhinitis, Allergic - epidemiology
Rhinitis, Allergic, Seasonal - drug therapy
Rhinitis, Allergic, Seasonal - epidemiology
Seasons
Sensitivity analysis
Surveys and Questionnaires
treatment adherence
Young Adult
Title Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcea.70004
https://www.ncbi.nlm.nih.gov/pubmed/39956639
https://www.proquest.com/docview/3177213000
https://www.proquest.com/docview/3167719129
https://pubmed.ncbi.nlm.nih.gov/PMC11908838
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-557931
Volume 55
WOSCitedRecordID wos001489641800011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1365-2222
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0003598
  issn: 0954-7894
  databaseCode: DRFUL
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9UwEB6WXRVfvKy36rpEUfCl0qZtkupT2bMHwd3lsBc5byXNxVOQHjlnj7Bv_gR_o7_ESXrBsgqCL6UlE0qSmclMMvMNwCuaKcupFS6IwYSpVCqUkRGhdbAA-JlUyicKH_GTEzGf57MteN_nwrT4EMOBm5MMr6-dgMtq_ZuQKyPf8shjge7EcSJc3QaazgY17KDpWqC9NOQiTztYIRfGM3Qdb0bXLMzrgZIdnOjYkvVb0fTufw3iHtzpLFBStCxzH7ZMsws325qUV7tw67i7bX8AVaEXbTYguVyS8z4kndQNKVwGISpNcrqoXfjRmkx8viNBe5LM3GFEQ86MRGPeUbdH_u9IQY6Ls48_v_-Q9Yq4CMarh3AxPTw_-BB2NRlChdKbom6UjHKTxBU1rEp5ZqiMrGFUOXFmNrVUMcm4Yoyjr4gGhpZGJ1LHuc0ToZNHsN0sG_MESMo017bKRaZZWlEq8FPLKNJVjK6y1QG86RenVB1guaub8aXsHRecvdLPXgAvB9KvLUrHn4j2-hUuO0Fdl2g-oQ-cYHsAL4ZmFDF3byIbs9w4GsY5-rU0D-BxyxDDX3xmMFp5AYgRqwwEDr573NLUCw_jHccuxiwRAbxuuWrUZ1J_Ksrl6nO52ZRZhlo0xvnwrPT3EZYHh4V_efrvpM_gNnUljX1Y3R5sX6425jncUN-QdVb7XqTwyediH3Ymp9OLo19neiYX
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5V5XnhUV6BAgaB1EtQ4jh2grhEfaiou6sVXVBvlmM73UhVFm27SL3xE_iN_BLGzkOsChISt1geK7I9M54Zz3wGeENTXQlaZS6JwYZMaR2qyGZh5WABsJmU2hcKj8Rkkp2c5NMN-NDXwrT4EEPAzUmG19dOwF1A-jcp11a9E5EHA73G8JRxXE7ZdNDDDpuuRdpjochy1uEKuTyeYej6aXTFxLyaKdnhia6bsv4sOrj7f7O4B3c6G5QULdPchw3bbMGN9lXKyy24Oe7u2x9AWZh5Ww9ILhZk1ielk7ohhashRLVJPs1rl4B0TvZ8xSNBi5JMXTiiIcdWoTnvqNug_3tSkHFxfPTz-w9VL4nLYbx8CJ8P9me7h2H3KkOoUX4ZakfFqbBJXFLLSyZSS1VUWU61E2hesYpqrrjQnAv0FtHEMMqaRJk4r_IkM8kj2GwWjX0ChHEjTFXmWWo4KynNsGlUFJkyRme5MgHs9LsjdQdZ7l7OOJO964KrJ_3qBfB6IP3a4nT8iWi732LZieq5RAMKveAE-wN4NXSjkLmbE9XYxcrRcCHQs6V5AI9bjhj-4muD0c4LIFvjlYHAAXiv9zT13AN5x7HLMkuyAN62bLU2Zq_-UsjF8lSuVjJNUY_GuB6el_4-Q7m7X_iPp_9O-hJuHc7GIzn6ODl6Brepe-DYJ9ltw-bFcmWfw3X9Ddlo-cLL1y-9iyd6
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5VW6h64VFegQIGgcQlKHESO0Fcom5XoG5Xqz5Qb5ZjO2ykKlttu0i98RP4jfwSxs5DRAUJiVssjxXZnhnP2DPfALyhiSo5LVMbxGD8WCrly8CkfmlhAbAZFcolCk_5bJaenWXzDfjY5cI0-BD9hZuVDKevrYCbC13-JuXKyPc8cGCgm7EtIjOCzfHR5HTaa2KLTtdg7cU-T7O4RRaykTz94OF5dMPIvBkr2SKKDo1ZdxpN7v7fPO7BndYKJXnDNvdhw9Q7cLupS3m9A1uH7Yv7AyhyvWgyAsnVkpx0YemkqkluswhRcZKjRWVDkC7J2OU8ErQpydxeSNTk2Eg06C11c-3_geTkMD8--Pn9h6xWxEYxXj-E08n-yd4nv63L4CuU4Bj1o2SUmygsqGFFzBNDZVAaRpUVaVbGJVVMMq4Y4-gvopGhpdGR1GFWZlGqo0cwqpe1eQIkZprrssjSRLO4oDTFppZBoIsQ3eVSe_Cu2x2hWtByWzvjXHTOC66ecKvnweue9KJB6vgT0W63xaIV1kuBJhT6wRH2e_Cq70Yxs28nsjbLtaVhnKNvSzMPHjcc0f_FZQejpedBOuCVnsBCeA976mrhoLzD0MaZRakHbxu2GowZV19ysVx9Feu1SBLUpCGuh-Olv89Q7O3n7uPpv5O-hK35eCKmn2cHz2Cb2grHLspuF0ZXq7V5DrfUN-Si1YtWwH4BbVsokA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+to+Treatment+in+Allergic+Rhinitis+During+the+Pollen+Season+in+Europe&rft.jtitle=Clinical+and+experimental+allergy&rft.au=Sousa-Pinto%2C+Bernardo&rft.au=Costa%2C+El%C3%ADsio+M.&rft.au=Vieira%2C+Rafael+Jos%C3%A9&rft.au=Klimek%2C+Ludger&rft.date=2025-03-01&rft.issn=0954-7894&rft.volume=55&rft.issue=3&rft.spage=226&rft_id=info:doi/10.1111%2Fcea.70004&rft.externalDocID=oai_DiVA_org_uu_557931
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-7894&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-7894&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-7894&client=summon